glp 1 agonist history Discovery of GLP-1–Based Drugs for the Treatment of Obesity Glucagon-like peptide-1 receptor: mechanisms and
Description
2011;343:d5928
Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis
The effects of GLP-1RAs on multiple human organizations, source: reference [2] Data from Novo Nordisk's Phase III clinical trial showed that liraglutide 3.0 mg resulted in a 5% weight loss in approximately 62% of obese patients and a 10% weight loss in 34% of patients after a 56-week treatment period
Quantified metrics of gastric emptying delay by glucagon-like peptide-1 agonists: a systematic review and meta-analysis with insights for periprocedural management
